Add To Watchlist
Share URL
About The Company
Description
Lexicon Pharmaceuticals, Inc.
Read More
Overview
Value
1
Growth
25
Health
42
Management
64
Analyst Opinion
60
Total
37
All Scores Out Of 100
Best Features
- Has a low level of debt
- Low preportion of income is paid as dividend 0
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders 0
- Does not hold enough liquid assets to cover short term liabilities
- No margin of safety at their current market price
- Disliked by Twitter users
- Poor earnings and cashflow growth
Latest News

Nothing Ever Comes Easy For Lexicon, But Maybe Sotagliflozin Will Prevail In Heart Failure
Seeking Alpha | 13:00 Sun 25 Dec 2022
Read More →

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript
Seeking Alpha | 02:34 Thu 10 Nov 2022
Read More →

Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022
GlobeNewsWire | 13:58 Fri 4 Nov 2022
Read More →

5 Penny Stocks To Buy For Under $5
PennyStocks | 17:23 Fri 12 Aug 2022
Read More →
Market Peers
LXRX
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-149.21%
Revenue Growth (5 Year Average)
0.63%
Ratings Consensus
Neutral
Share Buybacks
-11.28%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 2.5 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-14.45%
PE/Earnings Growth
N/A
Price/Book
3.24x
Growth
Growth Score
25
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 0.63% is lower than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Earnings growth of -7.36% is lower than the market average (14.48%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 12.32% is lower than the market average (12.35%)
Revenue Growth
0.63%
Earnings Growth
-7.36%
Cashflow Growth
12.32%
Health
Health Score
42
Altman Z Score
N/A
Piostroski Score
2.00
Debt/Equity
N/Ax
Current Assets/Liabilities
N/Ax
Free Cashflow/Total Debt
N/Ax
Debt/Capital
N/Ax
Management
Management Score
64
Average Buybacks/Dilution
-11.28%
Recent Buybacks/Dilution
29.42%
5 Year Price Volitility
57.18%
Return On Assets
-82.96%
Return On Capital Employed
-63.51%
Return On Equity
7.63%
Return On Free Cashflow
79.40%
Return On Investments
N/A
Analysts
Analyst Opinion
60
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Lexicon Pharmaceuticals, Inc.
Currency
USD
Beta
1.351587
Vol Avg
416019
Ceo
Mr. Lonnel Coats
Cik
0001062822
Cusip
528872302
Exchange
NASDAQ Global Select
Full Time Employees
87
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2000-04-07
Address
8800 Technology Forest Pl
City
The Woodlands
State
TEXAS
Country
US
Zip
77381
Phone
12818633000
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
29
Twitter Sentiment
N/A
Stocktwits Sentiment
58.00